These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 22504690)

  • 1. [Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage III B breast cancer patient with giant skin ulceration].
    Takeda Y; Tanaka N; Konishi J
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):629-32. PubMed ID: 22504690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
    Koeberle D; Ruhstaller T; Jost L; Pagani O; Zaman K; von Moos R; Oehlschlegel C; Crowe S; Pilop C; Thuerlimann B;
    Endocr Relat Cancer; 2011 Apr; 18(2):257-64. PubMed ID: 21317203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
    Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
    Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
    Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
    Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
    Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
    J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
    Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
    Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
    Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
    Suzuki M; Kimijima I; Ishii M
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
    Tahover E; Sonnenblick A; Peretz T; Katz D
    Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.